<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303469</url>
  </required_header>
  <id_info>
    <org_study_id>F170519002</org_study_id>
    <nct_id>NCT03303469</nct_id>
  </id_info>
  <brief_title>Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: [18F]Fluoromisonidazole (FMISO) Imaging</brief_title>
  <official_title>Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: [18F]Fluoromisonidazole (FMISO) Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      [18F] FMISO PET to determine hypoxia in patients with HCC treated with TACE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II study will investigate the utility of [18F] FMISO in patients with
      hepatocellular carcinoma (HCC). This trial is designed to test the hypothesis that PET
      determined [18F]FMISO uptake will indicate tumor hypoxia in patients with HCC treated with
      trans-arterial chemo-embolization (TACE). We anticipate that [18F] FMISO PET/CT will advance
      our understanding of the role of hypoxia in HCC prior to treatment and that this knowledge
      will help design newer combination therapeutic trials for better treatment outcomes. [18F]
      FMISO PET/CT provides three parameters, tissue hypoxic volume (HV), maximum tissue to blood
      uptake ratio (T:Bmax) and tumor blood flow. Both pre-and post-therapy images will be examined
      to investigate changes in these parameters during the course of TACE treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitate HCC tumor hypoxia at baseline using FMISO PET.</measure>
    <time_frame>At baseline</time_frame>
    <description>Perform PET/CT imaging using FMISO at baseline to measure tumor hypoxia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure changes in HCC tumor hypoxia and blood flow after TACE, prior to radiotherapy.</measure>
    <time_frame>1 month post-TACE procedures and prior to SBRT</time_frame>
    <description>Perform PET/CT imaging using FMISO post-TACE and prior to SBRT to determine tumor hypoxia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure changes in treated HCC tumor hypoxia following TACE and radiotherapy</measure>
    <time_frame>1 month post-SBRT</time_frame>
    <description>Perform PET/CT imaging using FMISO post-SBRT to determine tumor hypoxia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>FMISO PET imaging post TACE and SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMISO imaging at baseline, post-TACE and post-SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMISO</intervention_name>
    <description>FMISO PET/CT imaging at baseline</description>
    <arm_group_label>FMISO PET imaging post TACE and SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMISO</intervention_name>
    <description>FMISO PET/CT post TACE</description>
    <arm_group_label>FMISO PET imaging post TACE and SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMISO</intervention_name>
    <description>FMISO PET/CT post SBRT</description>
    <arm_group_label>FMISO PET imaging post TACE and SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; 18 years of age) patients with documented HCC tumor mass &gt;3cm, who are
             scheduled to undergo TACE with additional SIRT

          -  The appropriate criteria for inclusion for this patient population are:

          -  Biopsy or radiological diagnosis of HCC (defined as Organ Procurement and
             Transplantation Network (OPTN*) Category 5 lesion either on CT or MRI)

          -  Scheduled for TACE (using doxorubicin-eluting beads) + SBRT

          -  Willingness to undergo PET/CT

          -  Able to lie on the imaging table for up to 1 hour.

          -  Able to provide signed informed consent.

          -  Women with childbearing potential must have a negative urine Î²-hCG test day of
             procedure

        Exclusion Criteria:

          -  Estimated life expectancy &lt;12 months or serious medical co-morbidities that would
             preclude definitive local therapy

          -  Unable to lie on the imaging table

          -  Age less than 18 years.

          -  Pregnancy or lactation

          -  Inability or unwillingness to provide informed consent.

          -  Weight &gt;500 lbs (the weight limit of the tomograph gantry table)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janis P O'Malley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janis P O'Malley, M.D</last_name>
    <phone>205-934-1388</phone>
    <email>jomalley@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB Advanced Imaging Facility</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Vetrano, RN</last_name>
      <phone>205-934-4080</phone>
      <email>mvetrano@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2017</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Janis P. O'Malley</investigator_full_name>
    <investigator_title>Principal Investigator, Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

